A Promising Drug Target: FABP2 (Fatty Acid-Binding Protein, Intestinal)

Target Name: FABP2

NCBI ID: G2169

FABP2

A Promising Drug Target: FABP2 (Fatty Acid-Binding Protein, Intestinal)

Fatty acid-binding protein (FABP) is a protein that plays a crucial role in the absorption of fatty acids from the intestine into the bloodstream. FABP is expressed in various tissues and cell types, including the intestine, pancreas, and liver, and its primary function is to bind fatty acids, thereby promoting their transport and uptake into the body. Abnormalities in FABP expression or function have been implicated in various diseases, including obesity, type 2 diabetes, and cardiovascular diseases. As a result, targeting FABP has emerged as a promising strategy for developing new therapeutic approaches for these diseases. In this article, we will explore FABP2, a potential drug target and biomarker, with a focus on its structure, function, and potential therapeutic applications.

Structure and Function

FABP is a member of the superfamily of transmembrane proteins, which are characterized by the presence of a transmembrane region and an intracellular or extracellular tail. FABP is characterized by a N-terminal transmembrane domain, a long terminal fragment (LTF), and a C-terminal cytoplasmic domain. The N-terminal transmembrane domain is responsible for the formation of an ion channel that facilitates the transport of fatty acids across the membrane. The LTF contains a series of variable regions that are involved in the binding of fatty acids. The C-terminal cytoplasmic domain is involved in the formation of a complex with various co-factors, including enzymes involved in the absorption of fatty acids from the gut lumen into the bloodstream.

FABP functions as a transporter for fatty acids across the intestinal epithelium. It is expressed in the basal layer of the intestinal epithelium and is involved in the transport of both free fatty acids (FFAs) and triglycerides. FABP has been shown to promote the uptake of FFAcs and TGcs across the intestinal epithelium, and is critical for the development of malabsorption diseases, such as inflammatory bowel disease (IBD) and non-alcoholic steatohepatitis (NASH).

FABP has also been shown to play a role in the regulation of inflammation and immune responses. It is a strong predictor of the development of various inflammatory diseases, including NASH and IBD, and has been shown to modulate the immune response by influencing the production of pro-inflammatory cytokines.

Potential Therapeutic Applications

FABP has emerged as a promising drug target due to its involvement in various diseases. Abnormalities in FABP expression or function have been implicated in obesity, type 2 diabetes, and cardiovascular diseases. Therefore, several compounds have been developed to target FABP, with the goal of promoting weight loss, improving insulin sensitivity, and reducing the risk of cardiovascular disease.

1. Fatty acid-lowering drugs: One of the most promising approaches to targeting FABP is the development of drugs that can reduce the levels of FFAcs in the body. Drugs such as orlistat, a fatty acid transporter inhibitor, and bupropion, an inhibitor of the uncoupling protein (UCP), have been shown to promote weight loss by inhibiting the absorption of dietary fat.

2. Insulin sensitivity drugs: Insulin sensitivity is a key feature of obesity and type 2 diabetes, and drugs that can improve insulin sensitivity may be an effective strategy for targeting FABP. Compounds such as rosuvastatin, a inhibitor of the enzyme HMG-CoA reductase, have been shown to improve insulin sensitivity in both humans and obese rats.

3. Cardiovascular disease drugs: FABP has also

Protein Name: Fatty Acid Binding Protein 2

Functions: FABPs are thought to play a role in the intracellular transport of long-chain fatty acids and their acyl-CoA esters. FABP2 is probably involved in triglyceride-rich lipoprotein synthesis. Binds saturated long-chain fatty acids with a high affinity, but binds with a lower affinity to unsaturated long-chain fatty acids. FABP2 may also help maintain energy homeostasis by functioning as a lipid sensor

The "FABP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FABP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets